

Doxorubicin Market to Grow at 6.8% CAGR, Reaching \$1.81 Billion by 2034

Rising cancer cases and advancement like nanomaterials are driving demand for chemotherapy drugs. The doxorubicin market is expanding as a key treatment option.

ROCKVILLE , MD, UNITED STATES,
February 14, 2025 /EINPresswire.com/
-- The [doxorubicin market](#) is expected to grow at a compound annual growth rate (CAGR) of 6.8% to reach US\$ 1.81 billion by the end of 2034, from an estimated US\$ 940.5 million in 2024.



One of the noteworthy developments in the doxorubicin market is the use of nanomaterials in cancer treatment. The demand for chemotherapy drugs is mostly being driven by the increase in cancer cases worldwide. Among the often utilized cancer drugs include cyclophosphamide, etoposide, docetaxel, adriamycin, and cisplatin.

Doxorubicin is the first line of treatment for cancer, which is one of the main causes of death worldwide. Since the 1960s, doxorubicin has been utilized as a chemotherapy medication. Doxorubicin is being used extensively to treat soft tissue cancer, bone sarcomas, and cancers of the thyroid, breast, ovary, and bladder. Within DNA base pairs, doxorubicin intercalates, breaking DNA strands and further suppressing the synthesis of DNA and RNA.

For More Insights into the Market, Request a Sample of this Report-
https://www.factmr.com/connectus/sample?flag=S&rep_id=7303

Originating from the fungus *Streptococcus peucetius*, anthracyclines, such as doxorubicin (Adriamycin®) and daunorubicin (Daunomycin, Cerubidine®), were initially employed as antibacterial agents.

It is anticipated that doxorubicin sellers will benefit greatly from the continued research efforts and growing campaigns by the various governments in the North American region to raise

awareness about cancer. Over the course of the forecast period, this region is expected to hold the largest revenue share in the global market.

What factors are impacting the global sales of doxorubicin?

The World Health Organization estimates that by 2050, there will be more than 30 million new instances of cancer worldwide.

Growing knowledge of cancer is leading to an increase in diagnostic tests, including biomarkers, which boosts sales of anti-cancer medications. Doxil is increasingly being used to treat metastatic breast cancer. Numerous research come to the conclusion that no single medication or treatment can effectively treat cancer.

Doctors therefore employ the cancer immunotherapy approach to get around this problem. The bulk of the time, surgical treatment is used to remove cancerous tumors. Peptide-based medications for the treatment of cancer are being developed, nevertheless, as a result of innovative delivery methods for cancer therapies.

The use of nanotechnology in cancer treatment is expected to increase the efficacy of doxorubicin medications. This technique uses nanoparticles (NPs) ranging in size from 1 to 100 nm to identify malignancy. Because of its small size and high surface volume ratio, nanomedicine can reach the target region and provide therapeutic benefits without causing any side effects.

Competitive Landscape

To introduce new drugs, major players in the doxorubicin market are spending money on research and development. Their market position and revenue shares are increased by the launch of cutting-edge cancer remedies. To expand their product offerings, they are also using tactics like partnerships, mergers, and acquisitions.

Johnson & Johnson finished purchasing Ambrx in 2024. Johnson & Johnson's dedication to prostate cancer innovation is anticipated to be reinforced by this acquisition, which will also result in the creation of targeted oncologic therapies and next-generation antibody medications.

Growth Drivers for the Doxorubicin Market

Rising Cancer Incidence: Doxorubicin, a crucial chemotherapy medication, is in high demand due to the rising incidence of several diseases, such as leukemia, ovarian, and breast cancer.

Expanding Use in Combination Therapies: The growing adoption of combination therapies, where doxorubicin is used alongside other chemotherapeutic agents, enhances its effectiveness

and market demand.

Advancements in Drug Delivery Systems: Innovations such as liposomal formulations (e.g., pegylated liposomal doxorubicin) are improving drug efficacy, reducing side effects, and expanding market potential.

Growing Geriatric Population: As cancer risk increases with age, the rising elderly population is contributing to the growing demand for effective chemotherapy treatments like doxorubicin.

Increasing R&D Investments: Pharmaceutical companies and research institutions are investing in clinical trials and new formulations to enhance doxorubicin's therapeutic efficiency and expand its applications.

Government Initiatives and Cancer Awareness Programs: The availability and cost of doxorubicin-based treatments are being fueled by supportive legislation, financing for cancer treatment, and awareness initiatives.

Expanding Healthcare Infrastructure in Emerging Markets: Growing investments in healthcare facilities and improved access to cancer treatment in developing regions are fueling the global demand for doxorubicin.

Get Customization on this Report for Specific Research Solutions-
https://www.factmr.com/connectus/sample?flag=S&rep_id=7303

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the ambulance cot market, presenting historical demand data (2018 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights into the market based on product (emergency cots, transport cots), technology (manual cots, pneumatic cots, electric cots), and end user (EMS service providers, hospitals, ambulatory service centers), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).

Checkout More Related Studies Published by Fact.MR Research:

[Hyperthermia Cancer Treatment Market](#): The global hyperthermia cancer treatment market is experiencing steady growth, driven by increasing cancer cases and the rising adoption of thermotherapy in cancer management. Hyperthermia treatment, which uses heat to destroy cancer cells, is gaining traction as a complementary therapy. Among the different device types, microwave hyperthermia devices remain the most widely used due to their multiple advantages, while ultrasound hyperthermia devices are expected to see faster growth. The market is also

expanding with advancements in technology and growing awareness of hyperthermia's potential benefits.

[Epirubicin Market](#): The epirubicin market is experiencing steady growth, driven by its increasing adoption in cancer treatment, particularly for breast cancer after surgery. As a widely used anthracycline chemotherapy drug, epirubicin is preferred over doxorubicin due to its lower risk of adverse effects. The demand for effective and safer oncology treatments continues to rise, further fueling market expansion. With ongoing advancements in chemotherapy and increasing cancer prevalence, the epirubicin market is expected to see sustained growth in the coming years.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States

S. N. Jha

Fact.MR

+1 628-251-1583

sales@factmr.com

This press release can be viewed online at: <https://www.einpresswire.com/article/786017749>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.